Medical management of status epilepticus: Emergency room to intensive care unit

• Published in: Seizure (London, England) Vol. 75; pp. 145 - 152
• Main Authors: Crawshaw, Ania A., Cock, Hannah R.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-02-2020
• Subjects: Benzodiazepines; Levetiracetam; Phenytoin; Status epilepticus; Treatment; Valproate; Treatment; Status epilepticus; Benzodiazepines; Phenytoin; Valproate; Levetiracetam
• ISSN: 1059-1311; 1532-2688
• DOI: 10.1016/j.seizure.2019.10.006

•Video of seizures in the emergency department can be vital for long term management.•Seizure control within 1–2 hours improves outcome in convulsive status epilepticus.•Non-IV formulations of Midazolam are recommended in the absence of IV access.•Valproate and levetiracetam are recommended and may be superior to phenytoin.•Three large phase IV randomised trials are expected to report soon.
In convulsive status epilepticus (SE), achieving seizure control within the first 1–2 hours after onset is a significant determinant of outcome. Treatment is also more likely to work and be cost effective the earlier it is given. Initial first aid measures should be accompanied by establishing intravenous access if possible and administering thiamine and glucose if required. Calling for help will support efficient management, and also the potential for video-recording the events. This can be done as a best interests investigation to inform later management, provided adequate steps to protect data are taken. There is high quality evidence supporting the use of benzodiazepines for initial treatment. Midazolam (buccal, intranasal or intramuscular) has the most evidence where there is no intravenous access, with the practical advantages of administration outweighing the slightly slower onset of action. Either lorazepam or diazepam are suitable IV agents. Speed of administration and adequate initial dosing are probably more important than choice of drug. Although only phenytoin (and its prodrug fosphenytoin) and phenobarbitone are licensed for established SE, a now considerable body of evidence and international consensus supports the utility of both levetiracetam and valproate as options in established status. Both also have the advantage of being well tolerated as maintenance treatment, and possibly a lower risk of serious adverse events. Two adequately powered randomized open studies in children have recently reported, supporting the use of levetiracetam as an alterantive to phenytoin. The results of a large double blind study also including valproate are also imminent, and together likely to change practice in benzodiazepine-resistant SE.